Sorry, you need to enable JavaScript to visit this website.

This site is intended for US healthcare professionals only.

BREXAFEMME® (ibrexafungerp, 150 mg per tablet) Logo

This site is intended for US healthcare professionals only.

WATCH THE MOA
✕
Image of BREXAFEMME® (ibrexafungerp tablets) savings card

Ditch the itch for less

Your patients may be able to save on BREXAFEMME

No generic equivalent available

Your patients can cure their yeast infections for as little as $301,2

To redeem, instruct patients to:

  • bullet-point-iconGo to BREXAFEMME.com/SAVINGS and print the BREXAFEMME Savings Card or text “SAVE” to “BREXA”* (27392)
  • bullet-point-iconCommercially insured patients may pay as little as $30
  • bullet-point-iconBring their prescription for BREXAFEMME and the print-out of the BREXAFEMME Savings Card or text with their savings code to the pharmacy
  • bullet-point-iconOut-of-pocket patients may pay as little as $175
  • bullet-point-iconGo to BREXAFEMME.com/SAVINGS and print the BREXAFEMME Savings Card or text “SAVE” to “BREXA”* (27392)
  • bullet-point-iconBring their prescription for BREXAFEMME and the print-out of the BREXAFEMME Savings Card or text with their savings code to the pharmacy
  • bullet-point-iconCommercially insured patients may pay as little as $30
  • bullet-point-iconOut-of-pocket patients may pay as little as $175
tick_image__alt

Need more info for your patients?

Download Savings Offer

Have questions? We can help. Call 1-844-431-9894.

*Message and data rates may apply. One message per request. Reply “HELP” for help and “STOP” to stop.

TERMS AND CONDITIONS

For Patients: Offer valid for eligible commercially-insured and cash-paying patients with a prescription for BREXAFEMME® (Ibrexafungerp) including a valid Prescriber ID#. If eligible, you may pay as little as $30, and the card will pay up to the maximum benefit. If cash-paying, you may pay as little as $175, and the card will pay up to the maximum benefit. For questions about the BREXAFEMME Savings Card call 1-844-431-9894.

To Pharmacists: By using this offer, you certify you have not submitted a claim for reimbursement of this Rx with any federal, state, or other government program. Participation must comply with all relevant laws and regulations as a pharmacy provider, and must comply with the terms and conditions below.

Pharmacist instructions for a patient with an Eligible Third Party: Submit claim to the primary Third Party Payer first, then submit balance due to Change Healthcare (as a Secondary Payer; copay-only billing using valid Other Coverage Code (e.g. 8, 3)). The patient may pay as little as $30, and the card will pay up to the maximum benefit. Reimbursement comes directly from Change Healthcare.

Pharmacist instructions for a cash-paying patient: Submit claim to Change Healthcare. Include valid Other Coverage Code (e.g. 0, 1). The card will pay up to the maximum benefit. After the offer is applied, the patient will be responsible for any remaining balance due. Reimbursement comes directly from Change Healthcare. For questions with processing, call the Change Healthcare help desk at 1-800-433-4893.

Terms and Conditions: Offer valid only in the United States. Offer not valid for those enrolled in Medicare, Medicaid, TRICARE or any other federal or state healthcare plan. If you are enrolled in a state or federal healthcare plan, you may not use this Savings Card (even if you elect to be processed as an uninsured/cash-paying patient). Offer will be accepted at participating pharmacies only. This offer is not health insurance.

By using this offer you agree to comply with terms of your health insurance contract which may require you to tell your insurer about the offer. It is illegal to sell (or offer to), purchase, or trade this offer. Offer is not transferable. Valid for one prescription. Not valid if reproduced. Void where prohibited by law. SCYNEXIS Inc., reserves the right to rescind, revoke, or amend this offer without notice at any time.

Discover efficacy that cures.1,2


See Trial Results

Deliver the cure with one-day oral dosing.1,2

See Dosing

SAY NO MORE to vaginal yeast infections. Prescribe BREXAFEMME today.

Request a Rep
✕

SAY NO MORE to vaginal yeast infections. Prescribe BREXAFEMME today.

Request a Rep
✕

Indication

BREXAFEMME® is a triterpenoid antifungal indicated for Treatment of VVC and Reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC) in adult and post-menarchal pediatric females.

Important Safety Information

Risk of Embryo-fetal Toxicity

  • BREXAFEMME is contraindicated in pregnancy because it may cause fetal harm based on findings from animal reproductive studies
  • For females of reproductive potential, verify that the patient is not pregnant prior to initiating BREXAFEMME treatment. Reassessing pregnancy status prior to each dose is recommended when BREXAFEMME is used monthly for 6 months for reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC)
  • Advise females of reproductive potential to use effective contraception during treatment of vulvovaginal candidiasis (VVC) and throughout the 6-month treatment period for reduction in the incidence of RVVC with BREXAFEMME and, for 4 days after the last dose
  • BREXAFEMME is contraindicated in patients with a history of hypersensitivity to ibrexafungerp
  • When administering BREXAFEMME with strong CYP3A inhibitors, the dose of BREXAFEMME should be reduced to 150 mg twice a day for one day. Administration of BREXAFEMME with strong CYP3A inducers should be avoided
  • Most common adverse reactions observed in clinical trials (incidence ≥2%) of VVC were diarrhea, nausea, abdominal pain, dizziness, and vomiting. Most common adverse reactions observed in a clinical trial of RVVC were headache, abdominal pain, diarrhea, nausea, urinary tract infection and fatigue

To report SUSPECTED ADVERSE REACTIONS, contact SCYNEXIS, Inc. at 1‑888‑982‑SCYX (1‑888‑982‑7299) or FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch.

  • BREXAFEMME is contraindicated during pregnancy and in patients with a history of hypersensitivity to ibrexafungerp
  • BREXAFEMME administration during pregnancy may cause fetal harm based on animal studies. Prior to initiating treatment, verify pregnancy status in females of reproductive potential and advise them to use effective contraception during treatment
  • When administering BREXAFEMME with strong CYP3A inhibitors, the dose of BREXAFEMME should be reduced to 150 mg twice a day for one day. Administration of BREXAFEMME with strong CYP3A inducers should be avoided
  • Most common adverse reactions observed in clinical trials (incidence ≥2%) were diarrhea, nausea, abdominal pain, dizziness, and vomiting

To report SUSPECTED ADVERSE REACTIONS, contact SCYNEXIS, Inc. at 1-888-982-SCYX (1-888-982-7299) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

To report SUSPECTED ADVERSE REACTIONS, contact SCYNEXIS, Inc. at 1-888-982-SCYX (1-888-982-7299) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information and Patient Information.

References

1. BREXAFEMME. Prescribing Information. SCYNEXIS, Inc.; 2021. 2. Data on file. SCYNEXIS, Inc., Jersey City. NJ.

Important Safety Information

Indication

/ / / /
BREXAFEMME is contraindicated in pregnancy because it may cause fetal harm based on findings from animal reproductive studies. For females of reproductive potential, verify that the patient is not pregnant prior to initiating treatment. Reassessing pregnancy status prior to each dose is recommended when BREXAFEMME is used monthly for 6 months for reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC). Advise females of reproductive potential to use effective contraception during treatment of vulvovaginal candidiasis (VVC) and throughout the 6-month treatment period for reduction in the incidence of RVVC with BREXAFEMME and for 4 days after the last dose.